Abstract
Fabry disease is an X-linked, multisystemic lysosomal storage disorder due to alpha-galactosidase A deficiency. It is characterized by the accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in biological fluids, vascular endothelium, heart, and kidneys. Treatment by enzyme replacement therapy has been shown to be beneficial in both males and females affected with the disease. In addition to Gb3, increased concentrations of globotriaosylsphingosine (lyso-Gb3) have recently been reported in urine and plasma of Fabry patients. The overall objective of this metabolomic study was to identify and characterize new potential plasma biomarkers in treated and untreated males and females affected with Fabry disease which might better reflect disease severity and progression. We employed a time-of-flight mass spectrometry metabolomic approach using plasma samples of Fabry patients compared to age-matched controls. We found three new lyso-Gb3 analogs in Fabry patients presenting m/z ratios at 802, 804, and 820. As previously detected by our group, we also found a m/z ratio of 784 corresponding to the lyso-Gb3 molecule minus two hydrogen atoms. Using exact mass measurements and tandem mass spectrometry, we confirmed that these analogs result from modifications of the lyso-Gb3 sphingosine moiety. We evaluated the relative plasma concentration by measuring area counts for each lyso-Gb3 analog. None of these analogs was detected in the majority of healthy controls. The relative concentration of each analog was higher in males compared to female Fabry patients. We demonstrated that mass spectrometry combined to a metabolomic approach is a powerful tool to detect and identify new potential biomarkers.
Keywords: Biomarkers, Fabry disease, globotriaosylsphingosine (Lyso-Gb3), metabolomics, OPLS-DA, plasma, Qtof mass spectrometry, multisystemic lysosomal, alpha-galact, glycosphingolipids
Current Medicinal Chemistry
Title:A Metabolomic Study Reveals Novel Plasma Lyso-Gb3 Analogs As Fabry Disease Biomarkers
Volume: 20 Issue: 2
Author(s): F.O. Dupont, R. Gagnon, M. Boutin and C. Auray-Blais
Affiliation:
Keywords: Biomarkers, Fabry disease, globotriaosylsphingosine (Lyso-Gb3), metabolomics, OPLS-DA, plasma, Qtof mass spectrometry, multisystemic lysosomal, alpha-galact, glycosphingolipids
Abstract: Fabry disease is an X-linked, multisystemic lysosomal storage disorder due to alpha-galactosidase A deficiency. It is characterized by the accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in biological fluids, vascular endothelium, heart, and kidneys. Treatment by enzyme replacement therapy has been shown to be beneficial in both males and females affected with the disease. In addition to Gb3, increased concentrations of globotriaosylsphingosine (lyso-Gb3) have recently been reported in urine and plasma of Fabry patients. The overall objective of this metabolomic study was to identify and characterize new potential plasma biomarkers in treated and untreated males and females affected with Fabry disease which might better reflect disease severity and progression. We employed a time-of-flight mass spectrometry metabolomic approach using plasma samples of Fabry patients compared to age-matched controls. We found three new lyso-Gb3 analogs in Fabry patients presenting m/z ratios at 802, 804, and 820. As previously detected by our group, we also found a m/z ratio of 784 corresponding to the lyso-Gb3 molecule minus two hydrogen atoms. Using exact mass measurements and tandem mass spectrometry, we confirmed that these analogs result from modifications of the lyso-Gb3 sphingosine moiety. We evaluated the relative plasma concentration by measuring area counts for each lyso-Gb3 analog. None of these analogs was detected in the majority of healthy controls. The relative concentration of each analog was higher in males compared to female Fabry patients. We demonstrated that mass spectrometry combined to a metabolomic approach is a powerful tool to detect and identify new potential biomarkers.
Export Options
About this article
Cite this article as:
Dupont F.O., Gagnon R., Boutin M. and Auray-Blais C., A Metabolomic Study Reveals Novel Plasma Lyso-Gb3 Analogs As Fabry Disease Biomarkers, Current Medicinal Chemistry 2013; 20 (2) . https://dx.doi.org/10.2174/092986713804806685
DOI https://dx.doi.org/10.2174/092986713804806685 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies Biochemical Markers and Risk Factors of Alzheimers Disease
Current Alzheimer Research On the Analysis of Fingertip Photoplethysmogram Signals
Current Cardiology Reviews Effect of Antipsychotic Drugs on Cerebrovascular Morbidity and Mortality: A Systematic Review
Current Drug Therapy Neuroinflammatory Markers in Spontaneously Hypertensive Rat Brain: An Immunohistochemical Study
CNS & Neurological Disorders - Drug Targets Enzymatic Processing of <i>Omega</i> 3 Long Chain Polyunsaturated Fatty Acid Oils
Current Nutrition & Food Science Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Prostacyclin Synthase Gene: Implication and Prevention of Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?
Current Pharmaceutical Design Ticagrelor: Long-Term Therapy in Patients with Coronary Artery Disease
Reviews on Recent Clinical Trials Pharmacologic Modulators of Soluble Guanylate Cyclase/Cyclic Guanosine Monophosphate in the Vascular System - From Bench Top to Bedside
Current Vascular Pharmacology Insights Into Early and Rapid Effects of Statin Therapy after Coronary Interventions
Current Pharmaceutical Design Pleiotropic Effects of ARB in Vascular Metabolism - Focusing on Atherosclerosis-Based Cardiovascular Disease
Current Vascular Pharmacology MRI of the Small and Large Bowel
Current Medical Imaging Colesevelam: A New and Improved Bile Acid Sequestrant?
Current Pharmaceutical Design Magnesium and Anaesthesia
Current Drug Targets General Perspectives for the Treatment of Atherosclerosis
Letters in Drug Design & Discovery Current Concepts on Prenatal Diagnosis and Management of Fetal Tachyarrythmias
Current Cardiology Reviews